At what enterprise value was Rovensa acquired in 2020?

During the acquisition of Rovensa by PARTNERS GROUP in 2020, the transaction's Enterprise Value is estimated to be in the range of 1b - 4b EUR.

What was the EV/EBITDA of Rovensa when it was acquired by PARTNERS GROUP?

The estimated EV/EBITDA multiple for Rovensa is in the range of 10x - 18x.

When was Rovensa acquired by PARTNERS GROUP?

Rovensa was acquired by PARTNERS GROUP in 2020.

What was the revenue of Rovensa at the time of the deal?

The revenue of Rovensa at the time of the deal is estimated to be in the range of 250M - 500M EUR.

What was the EBITDA of Rovensa during the acquisition?

Rovensa's EBITDA is estimated to be in the range of 50M - 100M EUR.

How is the data for the Rovensa acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the Rovensa deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.partnersgroup.com/news-and-views/press-releases/investment-news/detail?news_id=f4ef0401-6aff-442a-9d5b-6a7a55b3a8d8

← DATABASE

Home Database Industry & ManufacturingRovensa

07/2020

PARTNERS GROUP takes majority stake in Rovensa

PORTUGAL Chemicals & Materials / Specialty Chemicals EV 1b - 4b EUR

Context

By acquiring a major equity stake in Rovensa, Partners Group captures a highly resilient agricultural platform generating in annual revenue and significantly strengthens its exposure to sustainable biocontrol technologies. Finalized as a prominent cross-border private equity transaction, this deal orchestrates the structural exit of the historical financial sponsor, Bridgepoint, which transitions its controlling interest to the incoming asset manager based on an overall enterprise value of . This ownership transfer marks the culmination of a highly successful investment cycle for the exiting sponsor, which initially acquired the business in 2017 and subsequently drove significant scale through organic innovation and the rigorous execution of six strategic add-on acquisitions. Following the transaction, the executive management team, led by Chief Executive Officer Eric van Innis alongside Nuno Loureiro, will remain at the operational helm to maintain strict corporate continuity and execute the next phase of institutional growth alongside the new majority shareholder. Strategically, the infusion of fresh institutional capital is specifically designated to accelerate the development of the company's leading biological solutions portfolio, capitalizing on surging global demand for environmentally sustainable agricultural inputs. The financial backer's comprehensive value-creation roadmap also prioritizes continued geographic internationalization, sustained investments in research and development targeting high-growth market niches, and the pursuit of select programmatic acquisitions to continuously build out operational capabilities. The transaction execution mobilized a consortium of top-tier professional advisory firms to validate the investment thesis and structure the divestment process. On the sell-side, the exiting private equity group mandated HSBC and J.P. Morgan to act as lead financial advisors for the sale. Furthermore, McKinsey provided strategic commercial insights, PwC handled the financial auditing scopes, and Uría Menéndez delivered comprehensive corporate legal counsel throughout the competitive process.

It is worth noting that the fund Bridgepoint took control of Rovensa through an LBO in 2016.

-> Deep-dive in Industry & Manufacturing market trends

Target

Rovensa operates as a specialized provider of agricultural biosolutions and biocontrol technologies headquartered in Portugal. Founded in 1926, the independent industrial company engineers and formulates sustainable crop nutrition and protection products explicitly designed to enhance agricultural yields while minimizing ecological impacts. The operational architecture is rigidly organized into three distinct manufacturing and research divisions: BioNutrition, which supplies essential nutrients for healthy crop development; Crop Protection, which focuses on eliminating or preventing biological threats; and BioControl, which utilizes biological inputs such as plant extracts and micro-organisms. By deploying these specialized biorational and biostimulant portfolios, the enterprise assists farmers in addressing global food security challenges, combating agriculture's wider contribution to climate change, and cultivating healthy food. The organization maintains a vast international distribution footprint, ensuring its proprietary agricultural solutions are actively sold across more than 70 countries worldwide. Relying on robust, centralized research and development capabilities, the firm continuously innovates within high-growth market niches, providing critical technologies that mitigate natural resource degradation and biodiversity loss.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2020

2019

Other operations with Rovensa

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
12/2016	BRIDGEPOINT	Rovensa	PORTUGAL	Specialty Chemicals

REFERENCES

Valuation range: EV 1b - 4b EUR

Revenue range: 250M - 500M EUR

EBITDA range: 50M - 100M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Rovensa by PARTNERS GROUP are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Target: rovensa

Acquirer: partners group